

References

L-234

1. National Institutes of Health (NIH). Serious mental illness (SMI) among U.S. adults. 2017.
2. Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. *Am J Psychiatry*. 2000;157(2):229-233.
3. American Psychiatric Association (APA): Practice guideline for the treatment of patients with major depressive disorder, Third Edition, 2010.
4. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. *Am J Psychiatr*. 2006; 163:28–40.
5. Tansey KE, Guipponi M, Hu X, et al. Contribution of common genetic variants to antidepressant response. *Biol Psychiatry*. 2013;73:679–682.
6. Assurex Health, Inc. Genesight. 2017.
7. Altar CA, Carhart J, Allen JD, et al. Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical Studies. *Mol Neuropsychiatry*. 2015;1:145–155.
8. Rundell JR, Harmandayan M, and Staab JP. Pharmacogenomic testing and outcome among depressed patients in a tertiary care outpatient psychiatric consultation practice. *Transl Psychiatry*. 2011;1, e6.
9. Breitenstein B, Scheuer S, Pfister H, et al. The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study. *CNS Spectrums*. 2014;19:165–175.
10. Hall-Flavin DK, Winner JG, Allen JD, et al. Using a pharmacogenomics algorithm to guide the treatment of depression. *Transl Psychiatry*. 2012; 2:e172.
11. Hall-Flavin DK, Winner JG, Allen JD, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depression disorder in a psychiatric outpatient setting. *Pharmacogenet Genomics*. 2013;23(10):535-548.
12. Peterson K, Dieperink E, Anderson J, Boundy E, Ferguson L, Helfand M. Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder. *Psychopharmacology*. 2017;234:1649-1661.
13. Singh AB. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. *Clin Psychopharmacol Neurosci*. 2015;13:150–156.

14. Winner JG, Carhart JM, Altar CA, Allen JD, Dechairo BM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomics testing for major depression disorder. *Disc Med.* 2013;16(89):219-27.
15. Myriad Genetics, Inc. Myriad Announces GeneSight® Psychotropic Results from a Large Prospective Trial in Patients with Major Depressive Disorder. November 2, 2017.